The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > COMMENTARY
COMMENTARY
- Opdivo Offers Hope but Poses Challenges Too, Cautious Approach Needed to Expand Indications
April 27, 2015
- Will Japanese Drug Makers Become More Discerning in Unearthing Seeds?
April 17, 2015
- Patient Subsidy System Expanded for Intractable Diseases, What about Incentives for Drug Makers?
April 7, 2015
- Abe Pledges Biosimilar Promotion, but Doctor Misconception and Lack of Incentives Remain as Challenges
March 30, 2015
- SGLT-2 Inhibitor Sales Would Plunge If Used Only in Younger, Obese Patients, but Cautious Administration Warranted
March 17, 2015
- Uncertainty Swirling around Possible Drug Price Cuts for 3 Straight Years
March 16, 2015
- Drug Repositioning May Promise Greater Chance of Success, but Problems Remain
March 6, 2015
- As Adjuvant Development Race Heats Up, New Databases Could Turn Japan into Global Vaccine Powerhouse
February 16, 2015
- Japan Poised to Tap Its Version of “Compassionate Use” to Combat Challenges Left for Unapproved Drugs
February 2, 2015
- Open Innovation Bandwagon Gathers Pace for Efficient Drug Discovery
January 26, 2015
- Have AGs Finally Become a Good Option to Counter Generics?
January 19, 2015
- Will Legal Regulation Propel or Stymie Clinical Research? “Risk-Based” Approach Holds Key
January 13, 2015
- Can Pharmas and Wholesalers Work to Dispel “Negative Primary Margins on Sales”?
December 22, 2014
- April-Sept. Earnings Signal Watershed in Japan’s Shift to Generics
December 15, 2014
- Wonder Drug? Savior? Avigan Clinical Trial for Ebola May Not Provide Clear-Cut Answer
December 5, 2014
- Torii Eager to Carve Out New Market with Japan’s 1st Sublingual Allergen Immunotherapy
November 25, 2014
- Was Weak Yen a Plus for April-Sept. Earnings? Profits Partly Canceled Out by Higher R&D, Import Costs
November 18, 2014
- JPWA’s Uniform Tax Representation Will Benefit Wholesalers and Customers Alike
November 10, 2014
- Can a More-Open ICH Maintain “Tri-Polar” Leadership? - Key Focus at Lisbon Meeting
November 5, 2014
- Ex-Health Minister Tamura’s Clout Likely to Grow in Nagatacho
October 14, 2014
ページ
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…